喀什阳痿早泄治疗好的医院喀什性功能有障碍哪治疗,喀什怀孕一周不要怎么办,喀什割包皮费多少钱,喀什男科医院检查,喀什怀孕一般多久能用试纸测出来,喀什人工上环医院,喀什阴道紧缩术如何做

concerned about weaker economic growth being a reality for most advanced economies."Further mis-steps from European and US policymakers risk converting the cracks in their economies into a much deeper global system crisis which would have worrying economic and?social consequences," he warned.But Smith, whose bank is focusing on Asia to drive profit growth, remains optimistic for the outlook in the Asia-Pacific region.He said that the fact is that Australia is incredibly well positioned because of the nation's linkage to Asia, which remains the best performing part of the global economy.His comments came after ANZ reported a 1.45 billion U.S. dollars underlying profit for the June quarter, up 1.3 percent compared to the March quarter.

BEIJING, Sept. 25 (Xinhua) -- As China's economy has soared to the second place in the world, the country's scientific strength has also surged -- if only measured by the numbers.Chinese researchers published more than 1.2 million papers from 2006 to 2010 -- second only to the United States but well ahead of Britain, Germany and Japan, according to data recently published by Elsevier, a leading international scientific publisher and data provider. This figure represents a 14 percent increase over the period from 2005 to 2009.The number of published academic papers in science and technology is often seen as a gauge of national scientific prowess.But these impressive numbers mask an uncomfortable fact: most of these papers are of low quality or have little impact. Citation per article (CPA) measures the quality and impact of papers. China's CPA is 1.47, the lowest figure among the top 20 publishing countries, according to Elsevier's Scopus citation database.China's CPA dropped from 1.72 for the period from 2005 to 2009, and is now below emerging countries such as India and Brazil. Among papers lead-authored by Chinese researchers, most citations were by domestic peers and, in many cases, were self-citations."While quantity is an important indicator because it gives a sense of scientific capacity and the overall level of scientific activity in any particular field, citations are the primary indicator of overall scientific impact," said Daniel Calto, Director of SciVal Solutions at Elsevier North America.Calto attributed China's low CPA to a "dilution effect.""When the rise in the number of publications is so rapid, as it has been in China -- increasing quantity does not necessarily imply an overall increase in quality," said Calto.He noted the same pattern in a variety of rapidly emerging research countries such as India, Brazil, and earlier in places like the Republic of Korea."Chinese researchers are too obsessed with SCI (Science Citation Index), churning out too many articles of low quality," said Mu Rongping, Director-General of the Institute of Policy and Management at the Chinese Academy of Sciences, China's major think tank.SCI is one of the databases used by Chinese researchers to look-up their citation performance. The alternative, Scopus, provides a wider coverage worldwide."Chinese researchers from a wide range of areas and institutions are vying for publication, as it is a key criterion for academic appraisal in China, if not the only one. As a result, the growth of quality pales in comparison to that of quantity," said Mu, an expert on China's national science policy and competitiveness.On the other hand, China also falls behind the United States in multidisciplinary research, which is a core engine for scientific advance and research excellence.From 2006 to 2010, China published 1,229,706 papers while the United States churned out 2,082,733. According to a new metric introduced by Elsevier's Spotlight research assessment solution, China generated 885 competencies while the United States had 1,817.In other words, China's total research output is more than half that of the United States, while the number of competencies showing China's strength in multidisciplinary research is less than half that of the United States.Cong Cao, an expert on China's science and technology, put it more bluntly in an article he wrote: "When the paper bubble bursts, which will happen sooner or later, one may find that the real situation of scientific research in China probably is not that rosy."China has been investing heavily in scientific research and technological development in recent years to strengthen its innovative capacity, The proportion of GDP spent on R&D grew from 0.9 percent in 2000 to 1.4 percent in 2007, according to the World Bank.An IMF forecast in 2010 says China now ranks second globally in R&D spending. The IMF calculates China's R&D expenditure at 150 billion U.S. dollars when based on Purchasing Power Parity, a widely used economic concept that attempts to equalize differences in standard of living among countries.By this measure, China surpassed Japan in R&D spending in 2010.Many see China's huge investment in R&D as the momentum behind the country's explosive increase in research papers."Getting published is, in some ways, an improvement over being unable to get published," Mu said. "But the problem is, if the papers continue to be of low quality for a long time, it will be a waste of resources."In China, academic papers play a central role in the academic appraisal system, which is closely related to degrees and job promotions.While acknowledging the importance of academic papers in research, Mu believes a more balanced appraisal system should be adopted. "This is a problem with science management. If we put too much focus on the quantity of research papers, we leave the job of appraisal to journal editors."In China, the avid pursuit of publishing sometimes gives rise to scientific fraud. In the most high-profile case in recent years, two lecturers from central China's Jinggangshan University were sacked in 2010 after a journal that published their work admitted 70 papers they wrote over two years had been falsified."This is one of the worst cases. These unethical people not only deceived people to further their academic reputations, they also led academic research on the wrong path, which is a waste of resources," Mu said.A study done by researchers at Wuhan University in 2010 says more than 100 million U.S. dollars changes hands in China every year for ghost-written academic papers. The market in buying and selling scientific papers has grown five-fold in the past three years.The study says Chinese academics and students often buy and sell scientific papers to swell publication lists and many of the purported authors never write the papers they sign. Some master's or doctoral students are making a living by churning out papers for others. Others mass-produce scientific papers in order to get monetary rewards from their institutions.A 2009 survey by the China Association for Science and Technology (CAST) of 30,078 people doing science-related work shows that nearly one-third of respondents attributed fraud to the current system that evaluates researchers' academic performance largely on the basis of how many papers they write and publish.Despite rampant fraud, China will continue to inject huge money into science. According to the latest national science guideline, which was issued in 2006 by the State Council, the investment in R&D will account for 2.5 percent of GDP in 2020."If China achieves its stated goal of investing 2.5 percent of its GDP in R&D in 2020, and sustains its very fast economic growth over the next decade, it would quite likely pass the U.S. in terms of total R&D investment sometime in the late 2010s," said Calto, adding that it is also quite likely that at some point China will churn out more papers than the United States.According to Calto, China does mostly applied research, which helps drive manufacturing and economic growth, while basic research only accounts for 6 percent, compared with about 35 percent in Germany, Britain, and the United States, and 16 percent in Japan."In the long term, in order to really achieve dominance in any scientific area, I think it will be necessary to put significant financial resources into fundamental basic research -- these are the theoretical areas that can drive the highest level of innovation," Calto said.

SINGAPORE, Sept. 7 (Xinhua) -- Singapore scientists have found possible new ways to treat a type of aggressive breast cancer that is unresponsive to current forms of treatment, local broadcaster Channel NewsAsia reported on Wednesday.The team of scientists at the Genome Institute of Singapore ( GIS) and National University of Singapore (NUS), led by GIS senior group leader Qiang Yu, found that the enzyme EZH2 acts by inhibiting genes that stop the growth of tumors in the body.The insights could open the door to developing more effective treatment for fast spreading breast cancers, especially the estrogen receptor-negative breast cancer that is common all over the world.It was also found that through EZH2, cancer is promoted in the body by activating specific genes that impact breast cancer progression and cancer stem cell self-renewal.Yu said the new understanding on how EZH2 works as a cancer- causing gene in breast cancer has important therapeutic implication."The results suggest that small molecule drugs that block enzyme activity of EZH2 may not work for cancers caused by EZH2's activation genes," Yu said.Currently pharmaceutical companies have been developing drugs only to the block EZH2 enzyme activity so that tumor suppressers can perform their protective role in blocking cancer growth.Researchers said the next step would be to develop biomarkers to identify tumors with EZH2.This step would enable better treatment methods, with one of options being the development of therapies that shut down EZH2 completely and not just inhibit its enzymatic function.The findings have been published on the journal Molecular Cell.

TAIYUAN, June 18 (Xinhua) -- A Chinese medical university will join hands with the Massey University of New Zealand to set up a community clinic specializing in chronic diseases in north China's Shanxi Province.The community clinic in Taiyuan, the provincial capital city, will provide medical services to more than 7,500 residents in the city's Hanxiguandong community, Ma Qianjin, vice president of the Shanxi University of Traditional Chinese Medicine, said on Friday.Residents will be able to seek advice from both Chinese and New Zealand experts on how to prevent chronic diseases like diabetes, said Ma.The clinic, which is expected to open this year, will also provide residents with free health check-ups and create health records for them.Bruce Ullrich, a Massey University board member, said on Friday that the clinic will integrate Western service with traditional Chinese medical techniques in its prevention and treatment of chronic diseases."The community clinic will mainly focus on people with obesity, diabetes and other chronic diseases. The cost of disease prevention will be dramatically lower than the cost of treatment," said Ullrich.Zhang Xinwei, deputy director of the provincial science and technology bureau, said that if the clinic's practices are successful, the model may be adopted by other regions in China.

SYDNEY, Aug. 2 (Xinhua) -- Australia's general practitioners ( GPs) will not back the idea of routine prostate cancer tests for men as young as 40 despite growing calls for regular screening, the nation's largest professional general practice organization said on Tuesday.Spokesman for the Royal Australian College of General Practitioners (RACGP), Professor Chris Del Mar said there was not enough solid evidence to suggest major benefits from routine screening and that current tests were unable to detect "nasty" and potentially deadly forms of prostate cancer from ones that will not cause any harm."The problem is you end up treating lots of people who don't need to be treated," Del Mar said, adding that treatment could leave men impotent and with incontinence problems."You will treat 20 times as many people than would have ever been bothered by it. We don't yet know that treating prostate cancer is better than not treating it. We are not sure it does any good and could be doing more harm," he said.On the other hand, Australia's urologists and pathologists both want men aged 40 and over who are worried about developing the disease to be offered tests.The Royal College of Pathologists (RCPA) on Tuesday released an official recommendation on routine screening for men aged 40 and over if they were concerned about prostate cancer.The pathologists argue that blood tests for prostate cancer in men under 50 can predict their future risk of developing the disease by measuring their prostate specific antigen levels (PSA).They say that men with high PSA levels for their age should be tested annually, while those PSA levels are below the average could be tested less frequently.Their call for more routine testing contrasts with recommendations for GPs, whose `Red Book' medical guide does not support regular screening.Instead, it suggests GPs should inform men aged 50-70 of the risks and benefits of screening and only test if the patient requests one.RACGP spokesman Del Mar, who co-wrote the RACGP's recommendations, said while the Red Book was being revised "we are not going to liberalize it".Prostate cancer is one of the most common forms of cancer in Australia.About 20,000 cases of prostate cancer are diagnosed each year, with 3,300 men dying.Given the debate around prostate cancer tests, the Royal College of Pathologists wants to work with GPs, urologists and other medical organizations to develop a consensus on how and when to test for the disease, in a similar way to how experts approach breast cancer."It would be a good outcome for prostate cancer if we worked towards developing more of an umbrella document which reflected consensus among different stakeholder organizations. ," RCPA President Paul McKenzie said.